Text Size

Report of the TFOS/ARVO symposium on global treatments for dry eye disease: An unmet need

Sullivan D.A., Hammitt K.M., Schaumberg D.A., Sullivan B.D., Begley C.G., Gjorstrup P., Garrigue J.-S., Nakamura M., Quentric Y., Barabino S., Dalton M., Novack G.D.

  • 2012
  • Ocular Surface
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, 02114, MA, United States; Sjögren's Syndrome Foundation, Bethesda, MD, United States; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; TearLab Corporation, San Diego, CA, United States; School of Optometry, Indiana University, Bloomington, IN, United States; Resolvyx Pharmaceuticals, Bedford, MA, United States; Novagali Pharma, Evry, France; Santen Pharmaceutical Co., Nara, Japan; Iris Pharma, La Gaude, France; Clinica Oculistica, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy; Dalton and Associates, Reading, PA, United States; PharmadLogic, San Rafael, CA, United States

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022